Introduction
Early prediction of neurological outcome in patients surviving cardiac arrest is a challenging problem. A combined approach using clinical assessment, electrophysiological studies and biochemical markers has been proven reliable in predicting poor outcome and is currently used in most centres [
1‐
3].
Neuron specific enolase (NSE) is a gamma isomer of enolase that is located in neurons and neuroectodermal cells. Several studies have evaluated the significance of NSE to predict neurological outcome in patients after cardiac arrest. However, the results are not unanimous regarding outcome prediction and the best cutoff value for NSE [
3‐
5]. Most authors agree that the NSE serum level after 72 hours carries the highest predictive value for neurological outcome after resuscitation [
3,
5]. In the large Prognosis in Postanoxic Coma Study Group (PROPAC) all patients with NSE levels >33 μg/l at any time had an unfavourable outcome [
6].
With the introduction of mild therapeutic hypothermia (MTH) the treatment of patients after cardiac arrest has changed significantly in the last years. Only a minority of prognostication studies have included patients who underwent MTH after cardiac arrest. The guidelines published in 2006 by the American Academy of Neurology (AAN) on outcome prediction in comatose survivors after cardiac arrest recommend a cutoff of 33 μg/l, but were also mainly based on studies in patients not treated with hypothermia. Thus, there is an urgent need to re-evaluate the validity of previously established prognostic markers in survivors undergoing therapeutic hypothermia [
7]. Therefore we conducted an observational study comparing NSE levels in patients treated with MTH with historical non-hypothermia (NH) patients.
Materials and methods
The study protocol was approved by the local ethics committee on human research and is conducted in accordance with the guidelines of the Declaration of Helsinki. All data were collected within the normal daily intensive care routine in an anonymous fashion. The institutional review board therefore waived the need for informed patient consent. A total number of 230 patients was analyzed. The hypothermia group (n = 97) was generated between December 2006 and August 2008 from patients admitted to our medical intensive care unit (MICU) after cardiac arrest. All patients received MTH irrespective of the initial rhythm. A historical NH group in the era prior to hypothermia treatment was identified in a cohort of 133 patients admitted to our MICU between 2002 and 2004 after cardiac arrest. Detailed characteristics for all patients included in the study are given in Table
1. Therapeutic hypothermia was initiated after admission with an intravenous infusion of cold saline (4°C, 1,000 to 1,500 ml bolus) followed by surface cooling with commercially available non-invasive devices (ArcticSun2000
® Medivance, Louisville, Colorado, USA). The target temperature was maintained for 24 hours. Intravenous sedation and analgesia was induced in all patients by a combination of midazolam (0.125 mg/kg/h) and fentanyl (0.002 mg/kg/h) with dose adjustment as needed. Patients undergoing hypothermia received muscle relaxation with repetitive administration of pancuronium (0.1 mg/kg) in order to prevent shivering. Apart from therapeutic hypothermia, there was no further difference in critical care treatment between the two groups. In all patient's post-resuscitation treatment was conducted by physicians highly experienced in critical care according to standard operating procedures. NSE serum levels were measured 72 hours after admission to MICU with an enzyme immunoassay (Elecsys 2010, Roche Diagnostics GmbH, Mannheim, Germany). The identical test and the same laboratory were used in both groups compared in this study. Potential neurological outcome was assessed on the third day after admission to MICU by clinical examination, NSE serum levels and somato-sensory evoked potentials, when needed. In all patients, the decision to continue or discontinue treatment was taken considering the results of these tests and with the advice of an external neurologist.
Table 1
Baseline characteristics and neurological outcome of patients treated with mild therapeutic hypothermia (MTH) and non-hypothermia (NH) group
Baseline parameters | | | |
Age (years) | 64.3 (52.9 to 73.0) | 60.3 (51.5 to 70.0) | 0.123 |
Gender | | | |
female | 33 (24.8) | 21 (21.6) | 0.638 |
male | 100 (75.2) | 76 (78.4) | |
APACHE II score | 26.0 (20.0 to 32.0) | 31.0 (24.0 to 34.0) | 0.003 |
Cardiac arrest | | | |
Out-of-hospital | 101 (75.9) | 81 (83.5) | 0.190 |
In-hospital | 32 (24) | 16 (16.5) | |
Cardiac rhythm | | | |
Shockable rhythm | 73 (54.9) | 65 (67.0) | 0.077 |
Non-shockable rhythm | 60 (45.1) | 32 (33.0) | |
Cause of cardiac arrest | | | |
AMI | 82 (61.7) | 55 (56.7) | 0.688 |
Primary arrhythmia | 24 (18) | 22 (22.7) | |
Respiratory | 22 (16.5) | 18 (18.6) | |
Other | 5 (3.8) | 2 (2.1) | |
Bystander CPR | | | |
yes | 24 (18.0) | 38 (39.2) | <0.001 |
No | 109 (82.0) | 59 (60.8) | |
Time to ROSC (minutes) | 22 (14 to 30) | 20 (12 to 27) | 0.176 |
Total epinephrine dose (mg) | 3.0 (2.0 to 5.0) | 3.0 (1.0 to 4.5) | 0.039 |
Length of ICU stay (days) | 15 (7 to 26) | 13 (7 to 23) | 0.693 |
Neurological Outcome | | | |
CPC at ICU discharge | | | |
1 - good recovery | 16 (12) | 33 (34) | <0.001 |
2 - moderate disability | 14 (10.5) | 20 (20.6) | |
3 - severe disability | 5 (3.8) | 5 (5.2) | |
4 - vegetative state | 34 (25.6) | 5 (5.2) | |
5 - death | 64 (48.1) | 34 (35.1) | |
Clinical outcome was assessed at the time of discharge from ICU according to the Pittsburgh cerebral performance category (CPC) [
8]. CPC 1 to 2 were classified as a favorable neurological outcome whereas CPC 3 to 5 were regarded as an unfavorable outcome.
The STATA software (Version 10.0; StataCorp; College Station, Texas, USA) and R (Version 2.8.1; The R Foundation for Statistical Computing, Vienna, Austria) were used for statistical analysis. According to non parametric distribution, descriptive parameters are given as median and inter-quartile range (IQR). Univariate analysis of differences between hypothermia patients and the non-hypothermia group was performed by using the Mann-Whitney-U test for non-parametric unpaired data and Fisher's exact test for dichotomous variables. Linear regression was used to analyze the association of NSE and several independent variables. Logistic regression was performed to predict neurological outcome. The association of NSE and hypothermia treatment was analyzed by adding an interaction term into the logistic regression model. Akaike information criterion (AIC) was used to select the final model. ROC analysis was performed to evaluate the value of NSE for prediction of neurological outcome. Survival data were analyzed by the Kaplan-Meier method and comparison between groups was performed by using the log-rank test.
Discussion
Determination of serum NSE is an established tool for outcome prediction after cardiac arrest [
5,
9,
10]. Nevertheless, post-resuscitation care has changed considerably with the introduction of therapeutic hypothermia in recent years. In general, outcome prediction may be more difficult in patients treated with hypothermia [
11,
12]. In particular, the role of NSE levels for outcome prediction in patients treated with MTH has only been investigated in a few studies with conflicting results [
13,
14]. Therefore, the predictive value of NSE in patients receiving MTH treatment requires re-evaluation.
The univariate analysis in the present study revealed a significantly lower median NSE serum level (72 hours after admission to hospital) under mild hypothermia compared to the non-hypothermia group. This result is in line with the published hypothesis of Tiainen
et al. that the neuroprotective effect of hypothermia would be accompanied by diminished release of NSE [
14]. Tiainen
et al. analyzed the effect of therapeutic hypothermia on levels of serum NSE performing serial measurements at 24, 36 and 48 hours after cardiac arrest. In a repeated measurement analysis the levels of NSE were significant lower in patients treated with hypothermia compared to control group. However, the median of NSE at 48 hours (7.9 μg/l; IQR, 5.9 to 13.9 μg/l) in the hypothermia group was only slightly lower compared to the control group (median 8.6 μg/l; IQR, 5.2 to 20.2 μg/l). After adjusting our data for confounders, hypothermia treatment showed only a trend to lower NSE values without reaching significance. However, the low r-square of this model indicates that further unknown important factors may be relevant.
To analyze the association of NSE, neurological outcome and MTH treatment after cardiac arrest, we used a logistic regression model revealing that the neurological outcome was associated with hypothermia treatment and the interaction term of NSE and hypothermia treatment. This interaction demonstrates that the relation between NSE and neurological outcome is modified by hypothermia treatment (Figure
3). Thus, the effect of hypothermia on neurological outcome differs substantially in comparison to the non-hypothermia group, depending on serum NSE level at 72 hours. The greatest therapeutic effect of hypothermia was observed in patients with NSE levels between 20 and 80 μg/l whereas in patients with high (>80 μg/l) or low (<20 μg/l) NSE levels the difference to patients not treated with hypothermia proved to be limited. Therefore, MTH may not only result in lower NSE levels but it appears to be associated with the probability of a better neurological outcome in patients treated with MTH in comparison to NH patients with similar NSE levels.
The results of the ROC analysis are a further indicator that the relation between NSE and neurological outcome is substantially modified by hypothermia treatment as the non-hypothermia group revealed a higher area under curve (AUC, 0.94) compared to the hypothermia group (AUC, 0.88). This trend towards a reduced discriminatory power of serum NSE levels for poor neurological outcome under hypothermia treatment was also found by Tiainen
et al. with an AUC of 0.89 in the control group compared to an AUC of 0.80 [
14].
In our series, cutoff values predicting unfavorable outcome (CPC 3 to 5) with a specificity of 100% were higher in the MTH group (78.9 μg/l) compared to NH group (26.9 μg/l) resulting in a cutoff-ratio (MTH/NH) of 78.9/26.9 = 2.9. Tiainen
et al. published a cutoff of 25.0 μg/l for NSE at 48 hours predicting six-month neurological outcome with a 100% specificity after MTH and 8.8 μg/l for the NH group (cutoff-ratio, 25.0/8.8 = 2.84) [
14]. Although the level of NSE cutoff is lower compared to our study, the NSE-cutoff-ratios are similar. Oksanen
et al. found a cutoff of 33 μg/l of NSE at 48 hours predicting poor six-month neurological outcome with a specificity of 100% whereas Rundgren
et al. obtained a NSE cutoff of 27.7 μg/l at 48 hours and 27.3 μg/l at 72 hours [
15,
16].
The comparability of absolute NSE values for prediction of neurological outcome seems to be limited as cutoffs are presumably affected by multiple parameters including time to NSE measurement, laboratory immunoassay, cause of cardiac arrest, in-/out-of-hospital cardiac arrest, time to ROSC and outcome definition. Especially different methods of NSE analysis may interfere with a comparison of results from different laboratories. The present study assessed NSE values at 72 hours after admission to hospital. This time point was shown to be superior for prediction of neurological outcome in non-hypothermia cardiac arrest patients [
5,
9,
10]. However, the ideal time point for measurement of NSE in patients treated with MTH for predicting outcome is still unclear. In a recent study, ROC analysis of neurological outcome showed an almost similar AUC (0.84) for NSE at 72 hours compared to NSE at 48 hours (AUC 0.83), whereas the threshold with 100% specificity of NSE at 48 hours was associated with a higher sensitivity (67%) compared to NSE at 72 hours (50%) [
16]. Current published data suggest that the time course of NSE serum levels might be a better predictor for outcome than a single measurement of NSE.
This study also has some limitations that should be pointed out. Results were obtained from a single-centre trial using a retrospective sample of non-hypothermia patients rather than from a prospective randomized study. However, due to the fact that the current guidelines clearly recommend mild hypothermia treatment after cardiac arrest, a prospective randomized trial comparing hypothermia and non-hypothermia is ethically not acceptable. With our retrospective study design it cannot be excluded that along with the implementation of hypothermia treatment post-resuscitation care has developed and improved in general. Moreover, we did not collect data on neurological long-term outcome. However, it has been shown that CPC scores at hospital discharge may undergo only minor changes in the following six months [
17‐
19].
A general problem in all studies on prognostication is the fact that these trials are susceptible to
self-fulfilling prophecies. In our analysis, NSE levels were not blinded to the physicians in charge. Nevertheless, the process of decision making on therapy withdrawal in patients with poor neurological prognosis always consisted of a combination of clinical, electrophysiological and biochemical tests, which is in line with current practice [
1,
2,
20]. As stated in the method section, both groups of patients received full ICU support over the first three days. Furthermore the length of ICU stay was shorter in the hypothermia group compared to the control group.
From the pathophysiological point of view our data are somewhat surprising. According to our results, patients treated with hypothermia stand a good chance of recovery despite higher levels of NSE. However, it cannot be fully ruled out that higher NSE levels in the hypothermia group may partly be due to factors other than hypoxic brain damage, for example a higher proportion of patients with non-convulsive status epilepticus. A current study by DeGiorgio
et al. evaluated the NSE release in different subtypes of status epilepticus. The mean peak NSE level for non-convulsive status epilepticus was 37.83 ng/ml [
21]. Moreover, the incidence of non-convulsive status epilepticus in survivors after cardiac arrest undergoing hypothermia amounts to 10% and appears to herald a fatal disease course in most patients [
22]. Although we did not routinely perform electroencephalography in all patients, these data show that a higher incidence of status epilepticus does not sufficiently explain the differences in NSE levels between the groups.
Another possibility is that NSE serum levels reflect different mechanisms of neuronal damage that are differentially affected by MTH. Support for this hypothesis comes from investigation of stroke patients. Wunderlich
et al. measured NSE on admission and on each of the first four days after stroke [
23]. An early first NSE peak was interpreted as due to a rapid release out of the initially damaged tissue, followed by a second peak at 72 hours reflecting secondary mechanisms of brain damage, ongoing neuronal cell death or persistent disturbance of the blood brain barrier. NSE release in patients after resuscitation was found to peak after 72 hours in the majority of published studies including patients without hypothermia treatment. It remains to be demonstrated whether mild hypothermia treatment affects NSE release especially in the late phase after 48 to 72 hours where reperfusion injury, ongoing cell death, edema and dysfunction of the blood brain barrier take place. Therefore a different NSE kinetic in patients undergoing hypothermia is possible and the best time point for neurological outcome prediction with NSE is obviously still unknown in patients treated with MTH.
Acknowledgements
The authors would like to thank Astrid Caemmerer, who is a regular employee of the Charité Universitätsmedizin-Berlin, for assistance and support with office work throughout the study.
This work was supported by Medivance Inc., Louisville, Colorado, USA with technical equipment; there was no direct financial support and Medivance had no influence on the study design, data analyses and interpretation, the content of the manuscript and no influence on the process of submission.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CS, IS, ED, and DH designed and supervised the analyses and analyzed all data. JS, FM and JN were involved in the collection of all data and participated in the data analyses. CP, AJ and AK participated in the design of the study, revised the manuscript for important intellectual content, and helped to draft the manuscript. DH and IS contributed equally to this work. All authors read and approved the final version of the manuscript.